{"id":538991,"date":"2021-04-16T19:40:02","date_gmt":"2021-04-16T19:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538991"},"modified":"2021-04-16T19:40:02","modified_gmt":"2021-04-16T19:40:02","slug":"adrenoleukodystrophy-market-size-share-trends-competitive-analysis-market-research-and-forecast-report-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adrenoleukodystrophy-market-size-share-trends-competitive-analysis-market-research-and-forecast-report-2030-by-delveinsight_538991.html","title":{"rendered":"Adrenoleukodystrophy Market Size, Share, Trends, Competitive Analysis, Market Research and Forecast Report 2030 by DelveInsight"},"content":{"rendered":"
\"Adrenoleukodystrophy<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Adrenoleukodystrophy Market Insights, Epidemiology and Market Forecast-2030\u2019 report delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.\n<\/div>\n

DelveInsight launched a new report on Adrenoleukodystrophy Market Insights, Epidemiology and Market Forecast 2030<\/strong><\/a>.<\/p>\n

DelveInsight’s ‘Adrenoleukodystrophy Market Report 2030<\/a>’<\/strong> delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n

Adrenoleukodystrophy is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. Currently, no drug is approved for the treatment of Adrenoleukodystrophy and the available treatment options include hormone replacement therapy, dietary therapy with Lorenzo’s oil and Hematopoietic stem cell transplantation, using either umbilical cord or bone marrow stem cells.<\/p>\n

View our full report: https:\/\/www.delveinsight.com\/report-store\/adrenoleukodystrophy-market<\/a><\/strong><\/p>\n

Adrenoleukodystrophy Symptoms:<\/strong><\/p>\n